|
Orthologous residues
|
|
WNK1 (human): T60‑p, WNK1 iso4 (human): T60‑p, WNK1 (mouse): T58‑p, WNK1 iso3 (mouse): T58‑p, WNK1 iso8 (mouse): ‑, WNK1 (rat): T58‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'stem, embryonic', 293 (epithelial)
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
activation of upstream enzyme, inhibition of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IGF-1
|
|
|
|
increase
|
|
|
LY294002
|
IGF-1
|
|
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
IGF-1
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
IGF-1
|
|
|
no effect upon treatment-induced increase
|
|
|
phorbol ester
|
|
|
|
increase
|
|
|
PD184352
|
phorbol ester
|
|
|
no effect upon treatment-induced increase
|
|
|
forskolin
|
|
|
|
increase
|
|
|
H-89
|
forskolin
|
|
|
inhibit treatment-induced increase
|
|
|
